STK32B

Summary

STK32B (serine/threonine kinase 32B, HGNC:14217) is a protein-coding gene on chromosome 4p16.2, encoding Serine/threonine-protein kinase 32B (Q9NY57).

This gene encodes a serine-threonine protein kinase. Serine-threonine kinases transfer phosphate molecules to the oxygen atoms of serine and threonine. A genomic deletion affecting this gene has been associated with Ellis-van Creveld syndrome, an autosomal recessive skeletal dysplasia. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 55351 — RefSeq curated summary.

At a glance

• GWAS associations: 11
• Clinical variants (ClinVar): 107 total
• Druggable target: yes — 5 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_018401

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14217
Approved symbol	STK32B
Name	serine/threonine kinase 32B
Location	4p16.2
Locus type	gene with protein product
Status	Approved
Aliases	STKG6, YANK2, STK32, HSA250839
Ensembl gene	ENSG00000152953
Ensembl biotype	protein_coding
OMIM	621309
Entrez	55351

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 4 protein_coding, 3 protein_coding_CDS_not_defined, 1 retained_intron, 1 nonsense_mediated_decay

ENST00000282908, ENST00000505508, ENST00000508728, ENST00000510398, ENST00000511959, ENST00000512018, ENST00000512636, ENST00000513705, ENST00000858431

RefSeq mRNA: 3 — MANE Select: NM_018401 NM_001306082, NM_001345969, NM_018401

CCDS: CCDS3380, CCDS77895

Canonical transcript exons

ENST00000282908 — 12 exons

Exon	Start	End
ENSE00001134909	5498945	5500989
ENSE00002042473	5051480	5051915
ENSE00003483724	5460103	5460228
ENSE00003522568	5331220	5331393
ENSE00003544445	5466703	5466834
ENSE00003557280	5168299	5168450
ENSE00003569809	5468006	5468070
ENSE00003593772	5446673	5446776
ENSE00003604538	5416845	5416934
ENSE00003615133	5398207	5398244
ENSE00003617576	5139905	5139960
ENSE00003642195	5456807	5456923

Expression profiles

Bgee: expression breadth ubiquitous, 177 present calls, max score 92.00.

FANTOM5 (CAGE): breadth broad, TPM avg 3.0390 / max 130.4464, expressed in 791 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
46751	2.6027	746
46750	0.2074	104
46752	0.1539	76
46749	0.0750	25

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	92.00	gold quality
buccal mucosa cell	CL:0002336	86.93	silver quality
oocyte	CL:0000023	86.35	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.70	gold quality
cortical plate	UBERON:0005343	83.97	gold quality
right testis	UBERON:0004534	80.75	gold quality
tibia	UBERON:0000979	80.26	gold quality
left testis	UBERON:0004533	79.91	gold quality
testis	UBERON:0000473	78.75	gold quality
adult mammalian kidney	UBERON:0000082	77.69	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	76.00	gold quality
metanephros cortex	UBERON:0010533	73.97	gold quality
kidney	UBERON:0002113	73.81	gold quality
germinal epithelium of ovary	UBERON:0001304	73.29	silver quality
islet of Langerhans	UBERON:0000006	71.89	gold quality
thymus	UBERON:0002370	71.50	silver quality
medial globus pallidus	UBERON:0002477	71.03	gold quality
cortex of kidney	UBERON:0001225	70.99	gold quality
skin of hip	UBERON:0001554	70.70	silver quality
body of stomach	UBERON:0001161	69.77	gold quality
subcutaneous adipose tissue	UBERON:0002190	69.66	gold quality
cartilage tissue	UBERON:0002418	69.13	silver quality
stomach	UBERON:0000945	69.01	gold quality
hypothalamus	UBERON:0001898	68.74	gold quality
ascending aorta	UBERON:0001496	68.45	gold quality
amygdala	UBERON:0001876	68.44	gold quality
sural nerve	UBERON:0015488	68.44	gold quality
ectocervix	UBERON:0012249	68.26	gold quality
thoracic aorta	UBERON:0001515	68.18	gold quality
omental fat pad	UBERON:0010414	67.68	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	54.46
E-ANND-3	yes	5.09

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

106 targeting STK32B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-767-5P	99.95	70.85	993
HSA-MIR-9718	99.94	68.91	918
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-498-3P	99.91	71.27	1114
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-6857-5P	99.87	65.32	985
HSA-MIR-4492	99.87	68.25	3611

Literature-anchored findings (GeneRIF, showing 7)

• In a consanguineous pedigree diagnosed with EvC and borderline intelligence, a 520-kb homozygous deletion comprising EVC, EVC2, C4orf6, and STK32B, caused by recombination between LINE-1 elements, was detected (PMID:18454448)
• STK32B and EVC yielded consistent evidence from cleft lip, with or without cleft palate, trios in all four populations. (PMID:20087401)
• STK32B association with essential tremor. (PMID:27797806)
• C allele of rs10937625 in STK32B is a protective factor for essential tremor in Chinese population. (PMID:28801652)
• This results of this study provided evidence that shifts in DNA methylation within the STK32B promoter are associated with a modulated risk profile for generalized anxiety disorder in adolescence. (PMID:29604450)
• Association Analysis of 27 Single Nucleotide Polymorphisms in a Chinese Population with Essential Tremor. (PMID:36929462)
• YANK2 activated by Fyn promotes glioma tumorigenesis via the mTOR-independent p70S6K activation pathway. (PMID:38714727)

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
danio_rerio	stk32a	ENSDARG00000079499
mus_musculus	Stk32b	ENSMUSG00000029123
rattus_norvegicus	Stk32b	ENSRNOG00000031397
drosophila_melanogaster	CG32944	FBGN0052944
drosophila_melanogaster	dop	FBGN0267390
caenorhabditis_elegans		WBGENE00002192
caenorhabditis_elegans	wts-1	WBGENE00007047
caenorhabditis_elegans		WBGENE00010838
caenorhabditis_elegans		WBGENE00011992

Paralogs (13): MAST4 (ENSG00000069020), MAST2 (ENSG00000086015), MAST3 (ENSG00000099308), SGK2 (ENSG00000101049), SGK3 (ENSG00000104205), DMPK (ENSG00000104936), MAST1 (ENSG00000105613), SGK1 (ENSG00000118515), MASTL (ENSG00000120539), LATS1 (ENSG00000131023), LATS2 (ENSG00000150457), STK32C (ENSG00000165752), STK32A (ENSG00000169302)

Protein

Protein identifiers

Serine/threonine-protein kinase 32B — Q9NY57 (reviewed: Q9NY57)

Alternative names: Yet another novel kinase 2

All UniProt accessions (3): Q9NY57, D6R9Y2, E9PCC0

UniProt curated annotations — full annotation on UniProt →

Miscellaneous. It is unsure whether Met-1 or Met-3 is the initiator.

Similarity. Belongs to the protein kinase superfamily. Ser/Thr protein kinase family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9NY57-1	1	yes
Q9NY57-2	2

RefSeq proteins (3): NP_001293011, NP_001332898, NP_060871* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site

Pfam: PF00069

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (12 total): sequence variant 5, binding site 2, chain 1, domain 1, region of interest 1, active site 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NY57-F1	86.38	0.70

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 146 (proton acceptor)

Ligand- & substrate-binding residues (2): 29–37; 52

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 124 (showing top): VERHAAK_AML_WITH_NPM1_MUTATED_DN, BENPORATH_ES_WITH_H3K27ME3, YANG_BREAST_CANCER_ESR1_LASER_UP, CCANNAGRKGGC_UNKNOWN, SMID_BREAST_CANCER_LUMINAL_B_UP, chr4p16, AACTTT_UNKNOWN, VANTVEER_BREAST_CANCER_POOR_PROGNOSIS, HOEBEKE_LYMPHOID_STEM_CELL_UP, MODULE_95, RIGGI_EWING_SARCOMA_PROGENITOR_UP, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, MULLIGHAN_MLL_SIGNATURE_2_DN, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_DN, GOMF_PROTEIN_KINASE_ACTIVITY

GO Biological Process (2): intracellular signal transduction (GO:0035556), protein phosphorylation (GO:0006468)

GO Molecular Function (8): protein serine/threonine kinase activity (GO:0004674), ATP binding (GO:0005524), metal ion binding (GO:0046872), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein kinase activity	2
intracellular anatomical structure	1
signal transduction	1
phosphorylation	1
protein modification process	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
cation binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1

Protein interactions and networks

STRING

982 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
STK32B	EVC2	Q86UK5	752
STK32B	CRMP1	Q14194	616
STK32B	STX18	Q9P2W9	602
STK32B	CTNNA3	Q9UI47	571
STK32B	LINGO1	Q96FE5	543
STK32B	TMEM114	B3SHH9	522
STK32B	CCDC183	Q5T5S1	519
STK32B	ZNF202	O95125	500
STK32B	ADTRP	Q96IZ2	497
STK32B	TRMO	Q9BU70	496
STK32B	TBX10	O75333	493
STK32B	HEMGN	Q9BXL5	491
STK32B	WNT11	O96014	490
STK32B	KCNS2	Q9ULS6	479
STK32B	SATB2	Q9UPW6	469

IntAct

3 interactions, top by confidence:

A	B	Type	Score
STK32B	HSP90AB1	psi-mi:“MI:0915”(physical association)	0.400
STK32B	GLRX3	psi-mi:“MI:0914”(association)	0.350

BioGRID (14): GLRX3 (Affinity Capture-MS), HLA-A (Affinity Capture-MS), HSPB1 (Affinity Capture-MS), DSP (Affinity Capture-MS), SERPINB3 (Affinity Capture-MS), MAPK12 (Affinity Capture-MS), LAGE3 (Affinity Capture-MS), GCN1L1 (Affinity Capture-MS), USP7 (Affinity Capture-MS), MMS19 (Affinity Capture-MS), OSGEP (Affinity Capture-MS), PNMA2 (Affinity Capture-MS), POLDIP2 (Affinity Capture-MS), STK32B (Affinity Capture-Luminescence)

ESM2 similar proteins: A0AUV4, A1A5Q6, A1A5R7, A2KF29, B1WAS2, C0HKC8, C0HKC9, O60285, O74536, O88831, O88866, P35125, P51956, P57058, Q20443, Q28283, Q2T9U5, Q4R9F7, Q5GLH2, Q5R669, Q5R7G9, Q5XHI9, Q66HE5, Q68UT7, Q6P431, Q6VZ17, Q7TNJ7, Q7TNL4, Q8BHI9, Q8BZN4, Q8C078, Q8C0N0, Q8C0V7, Q8C0X8, Q8K4K4, Q8NE63, Q8WP28, Q91VB2, Q92519, Q96L34

Diamond homologs: A1Z9X0, A2VDZ4, A7MB74, A8XJQ6, A8XNJ6, B2GUY1, B4IMC3, B4NSS9, F1M7Y5, F4HPN2, F4JY37, J9W0G9, M3TYT0, O00141, O15530, O55173, O70291, O74426, O75116, O77819, P05130, P09216, P10666, P10830, P11792, P12370, P13678, P16054, P18654, P23298, P25341, P26818, P28178, P28327, P32866, P34099, P34102, P34103, P34885, P36582

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

107 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	85
Likely benign	5
Benign	5

Top pathogenic / likely-pathogenic (0)

SpliceAI

3570 predictions. Top by Δscore:

Variant	Effect	Δscore
4:5104047:G:GG	donor_gain	1.0000
4:5139903:A:AG	acceptor_gain	1.0000
4:5139904:G:GA	acceptor_gain	1.0000
4:5139904:GT:G	acceptor_gain	1.0000
4:5139904:GTC:G	acceptor_gain	1.0000
4:5139904:GTCA:G	acceptor_gain	1.0000
4:5139904:GTCAA:G	acceptor_gain	1.0000
4:5139961:GTA:G	donor_loss	1.0000
4:5139962:T:G	donor_loss	1.0000
4:5168294:CTCAG:C	acceptor_loss	1.0000
4:5168295:TCA:T	acceptor_loss	1.0000
4:5168296:CAG:C	acceptor_loss	1.0000
4:5168297:A:C	acceptor_loss	1.0000
4:5168298:G:GA	acceptor_loss	1.0000
4:5168448:GTG:G	donor_gain	1.0000
4:5168450:GGT:G	donor_loss	1.0000
4:5168451:G:A	donor_loss	1.0000
4:5168451:G:GG	donor_gain	1.0000
4:5168452:T:G	donor_loss	1.0000
4:5168453:G:GT	donor_loss	1.0000
4:5331216:CTAG:C	acceptor_gain	1.0000
4:5331216:CTAGG:C	acceptor_loss	1.0000
4:5331217:TAGG:T	acceptor_gain	1.0000
4:5331218:A:AG	acceptor_gain	1.0000
4:5331218:AG:A	acceptor_gain	1.0000
4:5331219:G:GG	acceptor_gain	1.0000
4:5331219:GG:G	acceptor_gain	1.0000
4:5331219:GGT:G	acceptor_gain	1.0000
4:5331219:GGTA:G	acceptor_gain	1.0000
4:5331219:GGTAC:G	acceptor_gain	1.0000

AlphaMissense

2774 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:5139946:G:A	G32R	1.000
4:5139946:G:C	G32R	1.000
4:5139947:G:A	G32E	1.000
4:5139952:T:C	F34L	1.000
4:5139954:T:A	F34L	1.000
4:5139954:T:G	F34L	1.000
4:5139956:G:A	G35E	1.000
4:5168344:A:G	K52E	1.000
4:5168346:G:C	K52N	1.000
4:5168346:G:T	K52N	1.000
4:5398209:A:C	D146A	1.000
4:5416863:A:C	D164A	1.000
4:5416863:A:T	D164V	1.000
4:5416864:C:A	D164E	1.000
4:5416864:C:G	D164E	1.000
4:5466737:T:A	L315H	1.000
4:5466737:T:C	L315P	1.000
4:5139919:T:C	F23L	0.999
4:5139920:T:C	F23S	0.999
4:5139921:T:A	F23L	0.999
4:5139921:T:G	F23L	0.999
4:5139941:G:A	G30D	0.999
4:5139946:G:T	G32W	0.999
4:5139952:T:A	F34I	0.999
4:5139955:G:A	G35R	0.999
4:5139955:G:C	G35R	0.999
4:5139956:G:T	G35V	0.999
4:5168309:T:A	V40E	0.999
4:5168339:C:A	A50E	0.999
4:5168344:A:C	K52Q	0.999

dbSNP variants (sampled 300 via entrez): RS1000004059 (4:5239694 A>C), RS10000042 (4:5235425 C>T), RS1000005333 (4:5317907 A>G), RS10000062 (4:5253017 G>A,C,T), RS10000083 (4:5348125 G>A), RS10000145 (4:5295668 C>T), RS1000014876 (4:5479300 G>A,T), RS1000019709 (4:5381564 A>C,G), RS1000019901 (4:5066935 G>T), RS1000021702 (4:5143743 G>A,T), RS1000031634 (4:5474279 C>G), RS1000035320 (4:5239846 C>G), RS10000362 (4:5253306 G>A,C), RS10000376 (4:5411422 C>T), RS1000039451 (4:5175706 G>A,C,T)

Disease associations

OMIM: gene MIM:621309 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): long QT syndrome (MONDO:0002442)

Orphanet (1): Syndromic anorectal malformation (Orphanet:117573)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

11 associations (top):

Study	Trait	p-value
GCST001915_6	Alzheimer’s disease (cognitive decline)	5.000000e-07
GCST002090_2	Sensory disturbances after bilateral sagittal split ramus osteotomy	7.000000e-06
GCST002112_5	Celiac disease	8.000000e-06
GCST003762_7	Essential tremor	5.000000e-10
GCST005173_32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes	3.000000e-06
GCST006136_5	Alzheimer’s disease progression score	2.000000e-06
GCST006473_7	Diffusing capacity of the lung for carbon monoxide traits	6.000000e-07
GCST007600_6	Alzheimer’s disease	2.000000e-06
GCST008198_1	Vascular endothelial growth factor levels	5.000000e-10
GCST008771_1	Age at suicide	7.000000e-07
GCST90000015_1	Parkinson’s disease motor subtype (tremor to postural instability/gait difficulty score ratio)	7.000000e-07

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0005324	post-operative sensory disturbance
EFO:0004723	coronary artery calcification
EFO:0006514	Alzheimer’s disease biomarker measurement
EFO:0009369	diffusing capacity of the lung for carbon monoxide
EFO:0006882	suicide behaviour measurement
EFO:0600011	Parkinson’s disease symptom measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008133	Long QT Syndrome	C14.280.067.565; C14.280.123.625; C16.131.240.400.715; C23.550.073.547

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5912 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

5 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 21,390 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL180022	NERATINIB	4	9,404
CHEMBL223360	LINIFANIB	3	3,925
CHEMBL377300	BRIVANIB	3	1,721
CHEMBL603469	LESTAURTINIB	3
CHEMBL607707	PELITINIB	2	6,340

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — YANK family

Binding affinities (BindingDB)

4 measured of 4 human assays (4 total across all organisms); most potent 4 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
Staurosporine	KD	1.7 nM
4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole	KD	9.8 nM
4-[4-(4-fluorophenyl)-2-(4-methanesulfinylphenyl)-1H-imidazol-5-yl]pyridine	KD	12 nM
(E)-N-[4-(3-chloro-4-fluoro-anilino)-3-cyano-7-ethoxy-6-quinolyl]-4-(dimethylamino)but-2-enamide	KD	3500 nM

ChEMBL bioactivities

23 potent at pChembl≥5 of 26 total, top 19 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.62	Kd	24	nM	TAE-684
7.59	IC50	25.8	nM	STAUROSPORINE
7.34	IC50	45.2	nM	STAUROSPORINE
7.31	IC50	49.1	nM	STAUROSPORINE
7.01	Kd	98	nM	STAUROSPORINE
6.57	Kd	270	nM	LINIFANIB
6.35	Kd	446	nM	CHEMBL4465866
6.01	Kd	984	nM	CHEMBL4576489
6.00	IC50	1000	nM	TP-030-1
6.00	IC50	1000	nM	TP-030-2
6.00	IC50	1000	nM	TP-030n
5.92	Kd	1200	nM	CHEMBL386051
5.85	Kd	1400	nM	CHEMBL1241674
5.68	Kd	2100	nM	SB-203580
5.41	Kd	3900	nM	BRIVANIB
5.31	Kd	4900	nM	SB-202190
5.23	Kd	5900	nM	LESTAURTINIB
5.22	Kd	6000	nM	PELITINIB
5.19	Kd	6400	nM	NERATINIB

PubChem BioAssay actives

20 with measured affinity, of 239 total; 13 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
5-chloro-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine	625112: Binding constant for YANK2 kinase domain	kd	0.0240	uM
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	1715158: Inhibition of human STK32B using MBP as substrate by [gamma-33P]-ATP assay	ic50	0.0258	uM
1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea	436055: Binding constant for full-length YANK2	kd	0.2700	uM
3-(2,2-difluoro-10,12-dimethyl-1-aza-3-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-3,5,7,9,11-pentaen-4-yl)-N-[2-[2-[2-[2-[[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]amino]ethoxy]ethoxy]ethoxy]ethyl]propanamide	1526161: Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged STK32B (unknown origin) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	kd	0.4460	uM
3-(2,2-difluoro-10,12-dimethyl-1-aza-3-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-3,5,7,9,11-pentaen-4-yl)-N-[2-[2-[2-[2-[[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-methylamino]ethoxy]ethoxy]ethoxy]ethyl]propanamide	1526161: Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged STK32B (unknown origin) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	kd	0.9840	uM
6-(2,6-dichlorophenyl)-8-methyl-2-(3-methylsulfanylanilino)pyrido[2,3-d]pyrimidin-7-one	625112: Binding constant for YANK2 kinase domain	kd	1.2000	uM
2-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol	625112: Binding constant for YANK2 kinase domain	kd	1.4000	uM
4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine	436055: Binding constant for full-length YANK2	kd	2.1000	uM
(2R)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-ol	625112: Binding constant for YANK2 kinase domain	kd	3.9000	uM
4-[4-(4-fluorophenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]phenol	436055: Binding constant for full-length YANK2	kd	4.9000	uM
(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one	508132: Binding affinity to YANK2	kd	5.9000	uM
(E)-N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide	436055: Binding constant for full-length YANK2	kd	6.0000	uM
Neratinib	625112: Binding constant for YANK2 kinase domain	kd	6.4000	uM

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects expression, increases expression	2
Benzo(a)pyrene	affects methylation, increases methylation	2
bisphenol A	decreases methylation	1
arsenite	affects binding, decreases reaction	1
cobaltous chloride	decreases expression	1
zinc chromate	increases abundance, decreases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
chromium hexavalent ion	decreases expression, increases abundance	1
perfluorooctane sulfonic acid	decreases expression	1
jinfukang	affects cotreatment, decreases expression	1
theaflavin-3,3’-digallate	affects expression	1
Zoledronic Acid	decreases expression	1
Atrazine	increases expression	1
Caffeine	decreases phosphorylation	1
Cisplatin	decreases expression, affects cotreatment	1
Methapyrilene	increases methylation	1
Tobacco Smoke Pollution	increases methylation	1
Tretinoin	decreases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	increases expression	1
Aflatoxin B1	decreases methylation	1
Cadmium Chloride	increases expression	1
Particulate Matter	increases expression	1

ChEMBL screening assays

118 unique, capped per target: 118 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1045673	Binding	Binding affinity to YANK2 assessed as percentage of kinase remaining bound to the bead at 1 uM by T7 phage display based binding assay	Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). — J Med Chem

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TQ86	HAP1 STK32B (-) 1	Cancer cell line	Male
CVCL_TQ87	HAP1 STK32B (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

66 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02513940	PHASE4	COMPLETED	Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
NCT03834883	PHASE4	COMPLETED	Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
NCT04169100	PHASE4	UNKNOWN	Novel Form of Acquired Long QT Syndrome
NCT04675788	PHASE4	COMPLETED	Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
NCT01648205	PHASE2	COMPLETED	Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients
NCT02412709	PHASE2	UNKNOWN	Long QT Syndrome Screening in Newborns
NCT04581408	PHASE2	COMPLETED	Mutation-specific Therapy for the Long QT Syndrome
NCT00316459	PHASE1	COMPLETED	Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects
NCT01849003	PHASE1	COMPLETED	Study of the Effect of GS-6615 in Subjects With LQT-3
NCT02365532	PHASE1	COMPLETED	Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults
NCT02412098	PHASE1	COMPLETED	Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function
NCT02441829	PHASE1	COMPLETED	Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function
NCT05759962	PHASE1	COMPLETED	Phase 1 Study of LQT-1213 in Healthy Adults
NCT05906732	PHASE1/PHASE2	TERMINATED	Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).
NCT00005176	Not specified	COMPLETED	Long QT Syndrome-Population Genetics and Cardiac Studies
NCT00005250	Not specified	COMPLETED	Linkage Study of Long QT Syndrome In An Amish Kindred
NCT00005367	Not specified	COMPLETED	Epidemiology of Long QTand Asian Sudden Death in Sleep
NCT00221832	Not specified	UNKNOWN	Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases
NCT00292032	Not specified	COMPLETED	Registry of Unexplained Cardiac Arrest
NCT00335036	Not specified	TERMINATED	Pediatric Lead Extractability and Survival Evaluation (PLEASE)
NCT00399412	Not specified	COMPLETED	ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients
NCT00488254	Not specified	COMPLETED	The Long QT Syndrome in Pregnancy
NCT00588965	Not specified	COMPLETED	Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects
NCT01705925	Not specified	COMPLETED	Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome
NCT01903564	Not specified	COMPLETED	Fetal and Neonatal Magnetophysiology
NCT02082431	Not specified	COMPLETED	Determine the Incidence of Long QT Amongst a Large Cohort of Subjects Diagnosed With Unilateral or Bilateral Sensorineural Hearing Loss.
NCT02413450	Not specified	ENROLLING_BY_INVITATION	Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias
NCT02425189	Not specified	COMPLETED	The Canadian National Long QT Syndrome Registry
NCT02439645	Not specified	TERMINATED	A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes
NCT02439658	Not specified	UNKNOWN	Genetics of QT Prolongation With Antiarrhythmics
NCT02549664	Not specified	COMPLETED	Exercise in Genetic Cardiovascular Conditions
NCT02581241	Not specified	COMPLETED	Abnormal QT-Response to the Sudden Tachycardia Provoked by Standing in Individuals With Drug-induced Long QT Syndrome
NCT02680080	Not specified	COMPLETED	Effect of Grapefruit on QT Interval in Healthy Volunteers and Patients With Congenital Long QT Syndrome
NCT02775513	Not specified	UNKNOWN	Metabolism of Patients With Genetically Caused Cardiac Arrhythmia
NCT02814981	Not specified	UNKNOWN	Hydroxyzine and Risk of Prolongation of QT Interval
NCT02876380	Not specified	COMPLETED	Prospective Identification of Long QT Syndrome in Fetal Life
NCT03182777	Not specified	COMPLETED	Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies
NCT03544918	Not specified	COMPLETED	Prevalence of Congenital Long QT Syndrome and Acquired QT Prolongation in a Hospital Cohort
NCT03642405	Not specified	UNKNOWN	Drug-induced Repolarization ECG Changes
NCT03678311	Not specified	COMPLETED	Long QT Syndrome and Sleep Apnea